Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

3369 - Treatment patterns in elderly patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC): results from an EORTC led survey

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Tumour Site

Head and Neck Cancers

Presenters

Sjoukje Oosting

Citation

Annals of Oncology (2018) 29 (suppl_8): viii372-viii399. 10.1093/annonc/mdy287

Authors

S. Oosting1, I. Desideri2, D. Staelens3, C. Caballero3, S. Tribius4, C. Simon5, S. Singer6, V. Gregoire7, C. Fortpied3, A. Luciani8

Author affiliations

  • 1 Medical Oncology, University Hospital Groningen (UMCG), 9700 RB - Groningen/NL
  • 2 Radiation oncology, Università di Firenze- Dipartimento di Patologia e Oncologia Sperimentali, 50134 - Firenze/IT
  • 3 EORTC - European Organisation for Research and Treatment of Cancer, 1200 - Brussels/BE
  • 4 Radiation oncology, Asklepios Klinik St. Georg, 20099 - Hamburg/DE
  • 5 Otolaryngology/head And Neck Surgery, Centre Hospitalier Universitaire Vaudois - CHUV, 1011 - Lausanne/CH
  • 6 Institute Of Medical Biostatistics, Epidemiology And Informatics, Division Of Epidemiology, And Health Services Research, University Medical Center Mainz, 55131 - Mainz/DE
  • 7 Radiation oncology, Leon Berard Cancer Center, 69373 - Lyon/FR
  • 8 Medical Oncology, Azienda Ospedaliera S. Paolo, 20142 - Milan/IT

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3369

Background

An increase in the number of elderly patients diagnosed with head and neck cancer is expected, but there is no consensus on what is the optimal treatment for patients >70 years with locally advanced disease. Geriatric assessment (GA) is recommended but not validated for guiding treatment decisions. We hypothesized that significant heterogeneity will exist across institutions in patterns of care delivered to elderly patients with LA-HNSCC and in the use of GA and assessment of quality of life (QoL).

Methods

Members of the EORTC, the European Head and Neck Society and national groups in Europe were asked to complete a questionnaire about treatment delivered and use of GA and QoL assessment in elderly patients with LA-HNSCC.

Results

Investigators from 111 centers replied, including 90 (81.1%) academic centers, 16 (14.4%) community hospitals and 5 (4.5%) private clinics. Large differences in treatment patterns were found. For instance, for oropharyngeal carcinoma, one third of the centers indicate that they treat <5% of elderly patients with chemoradiation, while 18 centers (16.2%) treat >40% of elderly patients with chemoradiation. More than half of the centers hardly or never use cetuximab in elderly patients with hypopharyngeal carcinoma, while one in five centers treat >20% of the elderly patients with cetuximab. Furthermore, 3 centers (2.7%) treat <5% of elderly patients with oral cavity cancer with surgery and postoperative radiotherapy, while 73 centers (65.7%) offer this to at least 40% of their elderly patients. Fourteen centers (12.6%) routinely perform GA while 43 centers (38.7%) never do, and 39 centers (35.1%) sometimes do. QoL is assessed on a routine basis in one fifth of the centers.

Conclusions

Large differences exist across institutions in the patterns of care delivered to elderly patients with LA-HNSCC. Prospective studies are required in this population to learn how to use GA, how to improve QoL and ultimately improve treatment outcome. For that, consensus on standard of care is essential.

Clinical trial identification

Legal entity responsible for the study

EORTC.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

S. Oosting: Research grants (paid to institution): Pfizer, Novartis, Celldex. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.